Full-body MRI marketing: screening claims

Full-body MRI is sold straight to healthy adults who have no symptoms and no doctor asking for the scan. The pitch writes itself: one scan, head to hips, no radiation, find problems before they grow. That pitch is exactly where the legal and ethical risk sits, because the people buying the scan are well, and the claims made to them are health benefit claims about a screening test that federal regulators and the American College of Radiology have not endorsed for that use.

Two related topics have their own guides and are not repeated here. Physician referrals, the in-office imaging notice rule, accreditation and No Surprises Act points for radiology are in our imaging center marketing guide. Tests that consumers order themselves, including who may order and receive a result, are in our direct-to-consumer lab testing marketing guide. This guide covers what is specific to whole-body scans sold for screening. Packages that bundle several screening tests are covered in executive physical marketing. Another kind of elective imaging sold directly to consumers is covered in keepsake ultrasound studio marketing.

This is general information, not legal or medical advice. Who may order, perform and read a screening scan, and whether a given person should have one, are questions for licensed clinicians and your counsel, and the rules on ordering and supervision are set state by state. Sources cited were checked on October 30, 2026: the FDA page Full-Body CT Scans: What You Need to Know (content current as of December 5, 2017), the FDA pages MRI (Magnetic Resonance Imaging) (content current as of August 29, 2018) and MRI Benefits and Risks (content current as of December 9, 2017), the ACR Statement on Screening Total Body MRI (April 17, 2023), 15 U.S.C. 45 and 52, the FTC Health Products Compliance Guidance (December 2022), 16 CFR 255.2 and 255.5, and 45 CFR 164.508.

What the FDA and the ACR have said

Two public statements frame this category, and a scan center should know both before it writes a single ad, because a patient who searches for the service can find them in minutes.

The FDA’s consumer page on full-body CT scans, content current as of December 5, 2017, is about CT, which uses X-rays, not MRI. Its points on screening people without symptoms still describe the questions every whole-body screening service faces:

FDA says it knows of no scientific evidence demonstrating that whole-body scanning of individuals without symptoms provides more benefit than harm to people being screened.
FDA prohibits manufacturers of CT systems from promoting their use for whole-body screening of asymptomatic people, but it does not regulate practitioners, who may choose to use a device for any use they deem appropriate.
FDA writes that a whole-body CT screening exam won’t necessarily give people the “peace of mind” they are hoping for, that an abnormal finding may not be a serious one, that a normal finding may be inaccurate, and that “false” leads can prompt further, unnecessary testing.
FDA says whole-body CT screening has not been demonstrated to meet generally accepted criteria for an effective screening procedure, and that medical professional societies have not endorsed it for individuals without symptoms.
FDA recommends that a person carefully investigate and consider the potential risks and benefits and discuss them with their physician before a CT screening procedure.

The American College of Radiology addressed MRI directly. In its Statement on Screening Total Body MRI dated April 17, 2023, the ACR said that, at this time, it does not believe there is sufficient evidence to justify recommending total body screening for patients with no clinical symptoms, risk factors or a family history suggesting underlying disease or serious injury. It added that, to date, there is no documented evidence that total body screening is cost-efficient or effective in prolonging life, and that it is concerned such procedures will lead to the identification of numerous non-specific findings that will not ultimately improve patients’ health but will result in unnecessary follow-up testing and procedures, as well as significant expense. The ACR said it will continue to monitor scientific studies on the topic.

These are dated statements. Quote them with their dates, check them again before each campaign, and do not describe them as stronger or weaker than they are. Neither one bans the service; both are what an informed buyer will read.

Early detection, peace of mind and life-saving claims

Under 15 U.S.C. 45, deceptive acts or practices in commerce are unlawful, and 15 U.S.C. 52 makes it unlawful to disseminate a false advertisement to induce the purchase of services in or having an effect on commerce. The FTC Health Products Compliance Guidance says claims about the health benefits or safety of health-related products and services need competent and reliable scientific evidence, and that advertisers are responsible for each reasonable interpretation of an ad, including implied claims, not only the literal words.

Read the ad the way a healthy buyer would. The lines below each carry a health benefit claim that the evidence described by the FDA and the ACR does not support as a general promise:

“Catch cancer early” or “find disease before symptoms” implies that the scan finds disease reliably and that finding it earlier improves outcomes.
“Could save your life” or “add years to your life” is a survival claim. The ACR says there is no documented evidence that total body screening is effective in prolonging life.
“Peace of mind” implies that a clear result means good health. FDA says a normal finding may be inaccurate.
“Head-to-toe check” or “see everything” implies the scan covers every organ and condition. Say which regions and structures the protocol includes, and which conditions it is not designed to assess.
“Replaces your annual screenings” or anything close to it. A whole-body scan should not be presented as a substitute for screenings a patient’s own clinician recommends.

Plain descriptions carry less risk and still sell the service: what the scan is, which body regions it covers, how long it takes, who reads it, how results are delivered, and what happens if something is found. If you cite a study, name it, date it, and describe its population and limits accurately; a study of people with a known cancer syndrome does not support a claim about healthy adults.

“No radiation” is true; “risk-free” is not

MRI does have a real difference from CT, and it is fair to say so. FDA’s MRI Benefits and Risks page says MR images are made without using any ionizing radiation, so patients are not exposed to the harmful effects of ionizing radiation. The same page lists safety concerns that a screening service should not hide behind that point:

The strong static magnetic field attracts magnetic objects, which can become projectiles; FDA calls careful screening of people and objects entering the MR environment critical.
Implanted, external and accessory medical devices present unique hazards. FDA says patients with implanted medical devices should not receive an MRI exam unless the device has been positively identified as MR Safe or MR Conditional.
Radiofrequency energy can heat the body, and FDA says the potential for heating is greater during long examinations, which a whole-body protocol is.
Gradient fields create loud knocking noises that may harm hearing without adequate ear protection, and may cause a twitching sensation.
Gadolinium-based contrast agents, when used, carry their own risks, including allergic reactions.
Some patients find the scanner uncomfortably small and may experience claustrophobia.

So “no radiation” is an accurate comparison, while “safe”, “completely safe”, “risk-free” or “nothing to worry about” are not. Put the implant and device screening step on the booking page, before payment, so a buyer with a pacemaker, stimulator or other implant learns early whether the center can scan them at all.

Incidental findings: say what happens before they buy

The ACR statement names the central practical issue: non-specific findings that lead to follow-up testing and expense. For a healthy buyer, the follow-up is part of what they are buying, whether the ad mentions it or not. The sales page and the consent process should answer these questions in plain words before payment:

Who reads the scan, and what their qualifications are.
How results are delivered, how long that takes, and whether a clinician explains them or the buyer receives a report alone.
That findings of uncertain meaning are possible, and that a finding may lead to more imaging, lab tests or a biopsy recommended by another clinician.
That follow-up tests and visits are not included in the scan price, and that whether insurance pays for them depends on the buyer’s plan.
Whether the report can be sent to the buyer’s own clinician, and how the buyer authorizes that.
What the scan is not designed to assess, such as conditions for which the protocol is not built.

Leaving these points to the fine print invites the very complaint the FDA describes: a buyer who expected reassurance and received a referral list. Stating them up front is both fairer and a better test of whether a buyer is a good fit.

Ordering, supervision and who the scan is for

Whether a self-referred adult can book an MRI without an order from their own clinician, who must supervise the scan, and who may read it are set state by state. Do not write “no doctor’s order needed” or “no referral required” in an ad until counsel has confirmed it for each state where you take bookings.

The ACR statement is about people with no symptoms, risk factors or family history. A person with symptoms needs care from a clinician, not a consumer screening product. Ads and intake forms should say that anyone with symptoms should see their own clinician, and the booking flow should not encourage a person with new symptoms to wait for a screening slot instead.

Prices, memberships and financing

When whole-body scans are sold as self-pay services, price is a large part of the message. If you advertise a price, say what it includes: the scan, the read, any physician consultation, contrast if used and any repeat-scan membership terms. Self-pay patients are generally entitled to a good faith estimate under the No Surprises Act; our guides to good faith estimates, advertising cash prices and advertising patient financing cover those rules.

Annual or repeat-scan memberships deserve extra care. A membership tied to repeat screening implies that repeated scans benefit healthy people, which is the claim the FDA and ACR statements question. Describe the membership as a pricing option, not as a health plan.

Creators, referral codes and patient stories

Paid or gifted promotion brings in two sets of rules. Under 16 CFR 255.5, a connection between an endorser and the seller that might materially affect the weight or credibility of the endorsement, and that the audience would not reasonably expect, must be disclosed clearly and conspicuously; the rule says material connections can include payment or free or discounted products. A creator who received a free scan and posts about it has a connection to disclose. Our healthcare influencer marketing guide covers how.

A creator’s or patient’s story about a scan that “found something” is a claim made through an endorsement. Under 16 CFR 255.2(a) the advertiser must be able to substantiate it as if it had made the claim directly, and under 255.2(b) a story about a key attribute will likely be read as what buyers will generally achieve, so without substantiation the ad should clearly and conspicuously disclose the generally expected results. If the story comes from a patient’s own records, a written authorization under 45 CFR 164.508(a)(3) is needed before it is used in marketing.

Scan results are sensitive health information. Keep booking, intake and results pages free of ad tracking tools; see our guide to tracking pixels on practice websites.

Illustration: two ways to advertise a whole-body MRI service

Illustration: [Center name] runs a social ad that reads “Find cancer before it finds you. One scan, zero radiation, total peace of mind.” The landing page shows a creator’s video about a scan that “saved my life” with no disclosure that the scan was free, offers an annual membership described as “your yearly health check”, and asks about implants only after payment. The ad makes early detection, survival and reassurance promises the FDA and ACR statements do not support, the creator’s connection is undisclosed, and implant screening comes too late.

Illustration: [Center name] runs an ad that reads “Whole-body MRI, no ionizing radiation. Know what it can and cannot show before you book.” The landing page lists the regions scanned, names the reading radiologists, explains that findings of uncertain meaning are possible and that follow-up is not included in the price, quotes the FDA and ACR statements with their dates, asks the implant questions before payment, and tells anyone with symptoms to see their own clinician. A creator post carries a clear paid-partnership disclosure.

Checklist before a whole-body scan campaign goes live

No “catch cancer early”, “save your life”, “peace of mind” or “see everything” promises; any study cited is named, dated and described accurately.
“No radiation” is used only as a comparison with X-ray imaging, never as “safe” or “risk-free”.
Implant and device screening happens before payment.
Pages explain incidental findings, follow-up testing, what the price includes and what it does not.
Ordering, supervision and reading rules have been confirmed by counsel for each state where you take bookings.
Ads and intake tell people with symptoms to see their own clinician.
Paid or gifted creator posts carry a clear disclosure, and patient stories have written authorization.
Booking and results pages keep health information away from ad tracking tools.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices and health businesses. For an imaging center offering screening scans, that means service pages that explain what a scan can and cannot show, ads that describe the service rather than promise an outcome, and booking forms that ask safety questions early and keep health information away from tracking tools. We do not decide who should have a scan, how it is ordered or read, or whether a claim is substantiated; your clinicians and counsel do. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We are not a healthcare provider and we do not give legal or medical advice. We do not sell lead lists and we do not pay for referrals. For the wider rules, see our healthcare marketing rules hub.

Can we advertise that a full-body MRI catches cancer early?

Not as a general promise. Under 15 U.S.C. 45 and 52 and the FTC Health Products Compliance Guidance, health benefit claims need competent and reliable scientific evidence for each reasonable reading. The ACR said in April 2023 that it does not believe there is sufficient evidence to justify recommending total body screening for people without symptoms, risk factors or family history.

Is it accurate to say MRI uses no radiation?

Yes, as a comparison. FDA says MR images are made without ionizing radiation. FDA also lists MRI safety concerns, including hazards for people with implanted devices, heating during long exams, noise and contrast agent risks, so the scan should not be called risk-free.

Does the FDA statement on whole-body CT apply to MRI?

The FDA page is about CT, which uses X-rays. Its points about screening people without symptoms, such as abnormal findings that may not be serious, normal findings that may be inaccurate and follow-up testing, describe questions any whole-body screening service should answer, and the ACR statement addresses MRI directly.

Do we have to tell buyers about incidental findings?

Say before payment that findings of uncertain meaning are possible, that they may lead to more tests, and that follow-up is not included in the price. The ACR has said total body screening may lead to non-specific findings, follow-up testing and expense.

Can creators promote our scans?

Yes, with disclosure. Under 16 CFR 255.5, payment or a free or discounted scan is a material connection that must be disclosed clearly and conspicuously, and claims in the post must be substantiated as if the center made them.

Can we say no doctor’s order is needed?

Only after counsel confirms it. Ordering, supervision and reading requirements for imaging are set state by state.

Sources

More in Facilities, care services and pharmacy

Full-body MRI marketing: screening claims, incidental findings and what the FDA and ACR say